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Abstract We investigated whether muscarinic receptors of the 
MrM 4 receptor subtypes are constitutively active. We have 
found that the synthesis of cyclic AMP was enhanced by the 
muscarinic antagonists atropine and N-methylscopolamine 
(NMS) in Chinese hamster ovary (CHO) cells stably transfected 
with human m2 and m4 muscarinic receptor genes and in rat 
cardiomyocytes expressing the M2 receptor subtype, and that the 
production of inositul phosphates was inhibited by atropine and 
NVIS in CHO cells stably transfected with human ml and m3 and 
with rat ml muscarinic receptor genes. The muscarinic antago- 
nists quinuclidinyl benzilate and AF-DX 116 had no effect in some 
cases and acted like atropine and NMS in others. We conclude 
that the M~-M 4 subtypes of muscarinic receptors are constitu- 
tively active in the CHO cell lines expressing them and in cardi- 
omyocytes and that atropine and NMS act as negative antago- 
nists on these receptor subtypes by stabilizing them in the inactive 
conformation. 
antagonists permitted the demonstration of the constitutive 
activity of ~ opioid receptors [7], c~2-adrenoceptors [9], fl2- 
adrenoceptors [10-12], 5-hydroxytryptaminezc re eptors [13] 
and bradykinin receptors [14]. 
The present report describes the effects of four muscarinic 
antagonists on two processes which are controlled by muscar- 
inic receptors, namely the synthesis of cyclic AMP (normally 
inhibited by the M 2 and M 4 subtypes of muscarinic receptors) 
and the hydrolysis of phosphoinositides (normally activated by 
the Ml, M3 and M5 subtypes of muscarinic receptors - review 
[15]). No reports were available on the action of muscarinic 
antagonists applied alone on these processes by the time our 
experiments were started. Recently, however, Burstein et al. 
[16] described an inhibitory effect of atropine and pirenzepine 
on the hydrolysis of phosphoinositides in cells equipped with 
M3 muscarinic receptors and excess Gq protein. 
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1 Introduction 
It has been discovered recently that some of the receptors 
aich are coupled to G proteins display constitutive (spontane- 
ors) activity in the absence of agonists [1,2]. Most probably, 
sl,ch receptors oscillate between the inactive and the active 
c, .nformation [3,4] or one of the active conformations if these 
c,,nformations are multiple [5,6]. In the active conformation, 
they are able to activate the corresponding G protein. The 
b,nding of agonists hifts the equilibrium between the inactive 
a~d active receptors towards the active state. On the other 
hind, the binding of antagonists may have two different effects: 
s,,me antagonists do not distinguish between the inactive and 
a,:tive conformations and do not shift the equilibrium between 
t lem (neutral antagonists), while other antagonists bind prefer- 
e ~tially to the inactive receptors and shift the equilibrium in 
tJ,eir favour (negative antagonists) [7,8]. 
By decreasing the proportion of receptors which are in the 
sl~ontaneously active state the negative antagonists influence 
tl~e activity of G proteins and their effector molecules (enzymes 
and ion channels) in a direction which is opposite to the action 
o" corresponding agonists. Accordingly, the use of negative 
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2. Materials and methods 
2.1. Materials" 
[3H]adenosine (25 Ci/mmol), cyclic [14C]AMP (283 Ci/mol), [3H]inos- 
itol (83 Ci/mmol) and [~4C]inositol-l-phosphate (55 Ci/mol) were from 
Amersham Int. (Little Chalfont, UK). Dulbecco's modified Eagle's 
medium (Hybri-Max DME) and alumina WN/3 were from Sigma (St. 
Louis, MO), culture medium E-199 was from USOL (Prague, Czechia), 
the mixture of proteases (P-TC proteases for cell culture) was from TK 
Media Co. (Bratislava, Slovakia), and cytosine arabinoside was from 
Mack (Illertissen, Germany). Atropine sulphate and N-methylscopol- 
amine (NMS) were from Sigma (St. Louis, MO), R(-)-quinuclidinyl 
benzilate (QNB) was from RBI (Natick, MA), and AF-DX 116 (Ham- 
mer et al., 1986) was kindly provided by Dr. H. Ladinsky. 
2.2. Cells" and cell cultures 
Untransfected wild-type Chinese hamster ovary (CHO) cells were 
obtained from the American Type Culture Collection (Rockville, MD). 
CHO cell lines stably transfected with genes for the human M~, M2, M 3 
or M 4 subtypes of muscarinic receptors (subsequently denoted as hml 
hm4 genes and hM~-hM 4subtypes) [17] were kindly provided by Drs. 
T. I. Bonner and M. R. Brann. The gene for the rat M~ muscarinic 
receptor subtype (subsequently denoted as rml gene and rM~ subtype) 
was kindly donated by Dr. C. Fraser and subcloned into the pCMV-3 
mammalian expression vector supplied by Dr. D. W. Russell. CHO cells 
were co-transfected with pCMV-3 and pMSVneo and treated as de- 
scribed [18]. Clonal cell lines stably transfected with the rm 1 gene were 
screened to select cells which express high or low receptor number. The 
high-expression and the low-expression cell lines used contained 
41.5 + 5.2 fmol and 6.6 + 2.7 fmol of [3H]NMS binding sites (deter- 
mined as described [20]) per 1 million cells, respectively. Cell cultures 
were treated as described [18-20]. Cells were harvested using mild 
treatment with a mixture of proteases 4-5 days after subculturing. The 
binding properties of muscarinic receptors on the CHO cell lines ex- 
pressing the hml-hm4 genes and the rml gene were as determined by 
Jakublk et al. [20] and Zhu et al. [18], respectively. 
Cardiomyocytes were obtained from minced hearts of 4-day-old rats 
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by trypsin treatment and trituration. Fibroblasts were removed by 
preplating and 24 h exposure to cytosine arabinoside. Cells were grown 
in E-199 medium with 10% fetal calf serum. After 7 days in culture, they 
were harvested using mild treatment with a mixture of proteases, 
washed by repeated centrifugation and used for experiments. 
2.3. Assay of FH]cyclic AMP formation 
The method was modified from that described [19]. Cells were sus- 
pended in Krebs-Henseleit buffer, preincubated for 1 h at 37 °C with 
[SH]adenine (10/zCi/ml), washed twice by centrifugation and resus- 
pended in Kreb~Henseleit buffer containing 1 mM isobutylmethyl- 
xanthine. They were equilibrated for 15 min at 37 °C, after which they 
were incubated for 10 min with the investigated muscarinic ligand, with 
or without 20/zM forskolin. The incubation was in a volume of 0.8 ml 
per tube, with 300,000~00,000 cells per tube. It was stopped with 2.5 
M HCI and the content of the tube was applied on a column filled with 
1.5 g alumina [21,22]. The column was washed with 2 ml of 100 mM 
ammonium acetate (pH 7.0) and the retained cyclic [SH]AMP was 
eluted with 4 ml of 100 mM ammonium acetate and quantified by liquid 
scintillation spectrometry. Cyclic [~4C]AMP was used as standard to 
check the recovery. The synthesis of cyclic [~H]AMP was measured as 
the difference between the content of cyclic [3H]AMP in the samples at 
the end and in the beginning of the 10 min incubation period. 
2.4. Assay of the formation of [~H]inositol phosphates 
The assay was as reported [19] but diisoproplyfluorophosphate was 
not used. Inositol mono-, bis- and trisphosphate w re collected together 
as described [23] because their separation was unlikely to provide rele- 
vant additional information. 
2.5. Data analysis' 
Experiments were performed three times, with incubations in tripli- 
cates. The maximum effect (Emax) which a muscarinic ligand had on the 
measured parameter (the synthesis of cyclic [3H]AMP or of [3H]inositol 
phosphates) and the values of ECs0 (concentration f the ligand produc- 
ing one half of the maximum effect) and nH (Hill slope factor) were 
computed by fitting the following equation [24,25] to the data: 
[L]"~t (Eqn. l) 
E = 100 + Ernax × [L]n H + (ECs0)nH 
where E -- measured parameter (expressed as % of its control value) in 
the presence of muscarinic ligand L at the concentration [L], and Em,~ 
is the maximum effect expressed as % change of control value. 
Marqvardt's least square method with proportional weighting was used 
for the fitting. Statistical significance of differences from control values 
was evaluated with Student's t-test and differences at P < 0.05 were 
regarded as significant. 
3. Results and discussion 
3.1. Effects of muscarinic antagonists on the synthesis of  cyclic 
[SH]AMP in CHO cells expressing the hM 2 or hM 4 
subtype of muscarinic receptors and in rat cardiomyocytes 
Changes in the basal and the forskolin-stimulated rates of 
cyclic [3H]AMP accumulation were investigated. As shown in 
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Fig. 1. Effect of muscarinic antagonists on the synthesis of cyclic [3H]AMP in CHO cells expressing the human m4 (upper left) or m2 (upper ight) 
muscarinic receptor gene or in rat cardiomyocytes (lower right), either in the presence of 20/IM forskolin (full symbols) or in its absence (open 
symbols). Abscissa: log~0 of antagonist concentration (M). Left ordinate: cyclic [3H]AMP accumulation during 10 min incubation, expressed as a 
multiple of the basal accumulation rate observed in the absence of forskolin and antagonists, which was in the range of 85-107 fmol cyclic [SH]AMP 
per tube. Right ordinate: cyclic [SH]AMP accumulation, expressed as % of the basal unstimulated accumulation (for experiments without forskolin) 
or as % of the basal stimulated accumulation (in the presence of forskolin but without any antagonist). NMS, © e; atropine, []m; QNB, A, A; AF-DX 
116, v, v. Data are weighted means + S.E.M. of three experiments with incubations in triplicates. All increases in cyclic [SH]AMP accumulation 
observed in all three types of cells in the presence of atropine and NMS were statistically significant (P < 0.05) at 10 -9 M and higher concentrations 
but in some cases even lower antagonist concentrations caused a significant change. In experiments with cardiomyocytes, the effects of QNB were 
significant at 10 -9 5M and higher concentrations and the effects of AF-DX 116 were significant at 10 _75 M and higher concentrations. 
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F~g. 2. Effect of muscarinic antagonists on the production of [3H]inositol phosphates in CHO cells expressing the human ml (upper left) or m3 (upper 
ri!rht) muscarinic receptor gene or expressing the rat m l gene with a high density (lower left) or a low density (lower ight) of muscarinic receptors. 
Abscissa: log~0 of antagonist concentration (M). Ordinate: accumulation of [3H]inositol phosphates (IP~ = sum of inositol mono-, bis- and tris- 
pttosphate) during 60 min incubation i  the presence ofan antagonist, expressed asa multiple of the accumulation i  control samples without he 
a~tagonist; the latter value was in the range of 24-28 fmol [3H]inositol phosphates per tube. NMS, e; atropine, II; QNB, A; AF-DX 116, v, Data 
ale weighted means _+ S.E.M. of three xperiments with incubations intriplicates. All effects induced by atropine with all types of cells were statistically 
significant (P < 0.05) at concentrations of 10 -8.5 M and higher and those induced by NMS were significant at concentrations of 10 -8 M and higher. 
h the ceils with the high expression of the rml gene, significant changes were also observed at QNB concentrations of 10 -~° M and higher and at 
A F-DX 116 concentrations of I0  -7 M and higher. In the cells with the low expression ofthe rml gene, AF-DX 116 produced significant changes 
a ~ 10 -6 M and higher concentrations. 
Fig. 1, 20 pM forskolin itself increased the rate of cyclic 
[ H]AMP synthesis more than 18-fold in the hM2 and the hM 4 
t~ansfected CHO cells and more than 12-fold in cardiomy- 
o.:ytes. Its effect in the wild-type CHO cells was similar (not 
saown). Both the basal and the forskolin-stimulated rates of 
cmlic [3H]AMP accumulation were augmented by the muscar- 
i~Lic receptor antagonists atropine and NMS in all three cell 
t~.,pes examined, whereas QNB and AF-DX 116 had no effect 
~n CHO cells and a positive effect on cardiomyocytes. The 
c)mputed maximum effects induced by NMS and atropine 
~ere 33-54% in the cardiomyocytes and 8-20% in the trans- 
t~.zcted CHO cells (Table 1). The concentrations of antagonists 
producing half-maximal stimulation of cyclic [3H]AMP accu- 
i relation were in the range of 347-489 pM for atropine and 
110-126 pM for NMS. None of the four muscarinic antagonists 
l,:sted had any effect on the accumulation of cyclic [3H]AMP 
i l  the wild-type CHO cells when applied at the concentrations 
t~sed in Fig. I (not shown). 
The possibility that atropine and NMS produce their effects 
I'y preventing the action of endogenous acetylcholine (originat- 
i~lg from some unknown source) appeared unlikely because the 
experiments were performed in the absence of cholinesterase 
i~ahibitors and the enhancement of cyclic [3H]AMP accumula- 
tion by atropine and NMS was also observed at a time when 
the potent muscarinic antagonist QNB had no effect. In two 
experiments (performed with incubations in triplicates) which 
we made on cardiomyocytes, the addition of either ace- 
tylcholinesterase (10 units/ml) or eserine sulphate (50 ~M) to 
the incubation medium had no effect on the rate of cyclic 
[3H]AMP accumulation i the absence of NMS and did not 
change the stimulation of cyclic [3H]AMP accumulation i - 
duced by NMS. 
3.2. Effect of musearinic antagonists on the production of 
FH]inositol phosphates in CHO cells expressing the hM l, 
rM 1 or hM~ subtypes of muscarinic receptors 
The formation of [3H]inositol phosphates was diminished by 
atropine both in CHO cells expressing the hM / and hM 3 recep- 
tor subtypes and in CHO cells expressing the rM~ receptor 
subtype at high or low density (Fig. 2, Table 2). The effects of 
NMS were similar to those of atropine, but data obtained with 
NMS on cells expressing the hM1 receptor subtype did not fit 
Equation 1and relevant parameters ofNMS action were there- 
fore not computed in Table 2. QNB was without effect on cells 
expressing the hMl and hM3 receptor subtypes and on cells with 
low expression of the rM~ subtype, but it had an inhibitory 
effect on cells with a high expression of the rMj subtype. In the 
presence of AF-DX 116, the accumulation of inositol phos- 
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Table 1 
Quantitative parameters of the action of muscarinic antagonists on the synthesis of cyclic [3H]AMP in CHO cells expressing the human m2 or m4 
muscarinic receptor gene and in rat cardiomyocytes 
Ligand Forskolin CHO cells, hm2 gene CHO cells, hm4 gene Rat cardiomyocytes 
pECs0 Emax nH pECs0 Ema x nH pECs0 Em,x nH 
(% change) (% change) (% change) 
NMS 0 9.94 + 0.49 +16.4 + 0.8 
20/.tM 9.90+0.30 +11.5+0.5 
Atropine 0 9.41 + 0.26 +19.7 + 0.3 
20,uM 9.37_+0.03 +18.0_+ 1.1 
R(-)-QNB 0 no effect 
20/IM no effect 
AF-DX 116 0 no effect 
20 pM no effect 
1.03+0.01 9.95+0.42 +12.1+0.1 1.02+0.06 9.96+0.19 +49.1+2.4 1.08+0.00 
0.98+0.05 9.92+0.14 +8.1+0.3 1.03+0.07 9.92+0.23 +33.3+0.8 1.13+0.00 
0.95 + 0.00 9.46 +0.36 +15.0 + 0.4 1.01 + 0.02 9.36 +0.27 +54.3 + 0.9 0.89 + 0.04 
0.95 + 0.06 9.40 + 0.42 +13.5 + 0.2 0.97 + 0.06 9.31 + 0.21 +47.7 + 1.0 0.85_+ 0.01 
noeffect 10.4 +0.14 +11.0+0.4 1.17+0.02 
noeffect 9.95+0.11 +8.7+0.3 0.81 +0.02 
no effect 7.88 + 0.31 +17.0 + 0.3 1.18 + 0.05 
no effect 7.58 + 0.23 +13.0 + 0.2 1.18 + 0.02 
Values in the Table have been computed from the results of experiments shown in Fig. 1; they are weighted means + S.E.M. of three experiments 
with incubations in triplicates, pECs0 = -log~0 of the concentration fantagonist producing one half of the maximum effect; Em~x = maximum effect 
expressed as % of control value, with stimulation denoted by + and inhibition by - signs; nH= Hill slope factor. 
phates was inhibited in cells expressing the hMl or rM~ receptor 
subtypes. Conspicuously, the effects of atropine, NMS and 
AF -DX 116 were higher on the cells expressing the rMj recep- 
tor subtype at the high density than on those expressing it at 
the low density, and the effect of QNB was only apparent on 
the cells expressing the rM~ receptor subtype at the high density 
(Table 2). 
None of the four antagonists tested at the concentrations 
shown in Fig. 2 had any effect on the accumulation of [3H]inos- 
itol phosphates in untransfected (wild-type) CHO cells (not 
shown). 
3.3. Effects of  carbachol 
Functional responses to the stable muscarinic agonist car- 
bachol were tested in parallel experiments. At 1 pM concentra- 
tion, carbachol inhibited the rates of the basal and the fors- 
kolin-stimulated cyclic [3H]AMP accumulation in CHO cells 
expressing the hm2 and hm4 genes by more than 43% and in 
cardiomyocytes by more than 23%. The rate of the accumula- 
tion of [3H]inositol phosphates was enhanced 5.6-fold and 9.4- 
fold in CHO cells expressing the hml and hm3 genes, respec- 
tively, and 4.7-fold and 5.2-fold in CHO cells expressing the 
rml gene at the high and the low receptor density, respectively. 
3.4. Inferences 
By producing an increase in the synthesis of cyclic [3H]AMP 
in CHO cells expressing the M2 and M 4 muscarinic receptor 
subtypes and in rat cardiocytes and by diminishing the produc- 
tion of [3H]inositol phosphates in CHO cells expressing the M1 
and M 3 muscarinic receptor subtypes, the muscarinic antago- 
nists atropine and NMS had exactly opposite effects than the 
muscarinic agonist carbachol on these cells. It appears justified 
to assume that the effects of atropine and NMS were mediated 
by muscarinic receptors because they were not present in wild- 
type CHO cells untransfected with the receptor gene and the 
ECs0 values were close to those expected for the binding of 
atropine and NMS to muscarinic receptors [17,20]. 
On the other hand, the effects of QNB and AF-DX 116 
varied between cell types and receptor subtypes. Differences in 
the effects of different receptor antagonists on receptor activity 
have been noted in the work with ~ opioid receptors [7] and in 
subsequent studies on other types of G protein coupled recep- 
Table 2 
Quantitative parameters of the action of muscarinic antagonists on the synthesis of [3H]inositol phosphates in CHO cells expressing the human ml 
or m3 gene or the rat ml gene at two different levels of expression 
Ligand pECs0 Em,x nH pECs0 Era, x nH 
(% change) (% change) 
CHO cells, lunl gene CHO cells, hm3 gene 
NMS lack of fit 9.82 + 0.56 -19 + 1 0.88 + 0.01 
Atropine 8.58 _+ 0.17 -14 + 2 1.07 + 0.02 9.49 + 0.17 -14 + 0 1.20 + 0.03 
R(-)-QNB no effect no effect 
AF-DX 116 6.16 _+ 0.09 -24 + 2 0.99 + 0.01 no effect 
CHO cells, rml gene, high expression CHO cells, rml gene, low expression 
NMS 8.77 + 0.19 -15 _+ 2 1.11 + 0.00 8.69 + 0.09 -6 _+ 1 1.11 + 0.03 
Atropine 8.50 _+ 0.22 -13 _+ 1 1.13 + 0.02 8.21 + 0.14 -8 + 1 0.78 + 0.02 
R(-)-QNB 9.53 + 0.16 -16 + 1 0.92 + 0.03 no effect 
AF-DX 116 6.33 _+ 0.11 -23 _+ 2 1.01 + 0.02 6.14 + 0.08 -9 + 1 1.19 + 0.02 
Values in the Table have been computed from the results of experiments shown in Fig. 2; they are weighted means +S.E.M. of three experiments 
with incubations in triplicates, pECs0 = -log~0 of the concentration fantagonist producing one half of the maximum effect; Em, x = maximum effect 
expressed as% of control value, with stimulation denoted by + and inhibition by - signs; nH= Hill slope factor. 
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tots [10,11,13,14]. It has been predicted that the same antago- 
nist may have different effects on the same receptor subtype 
dcpending on the magnitude of the allosteric onstant describ- 
ing the equilibrium between the active and inactive receptors 
in a given cell population and on the stoichiometric ratio of 
receptors to G proteins [26]. The difference between the stoi- 
ct~iometric ratios of rM~ receptors and G proteins in cells with 
the high and the low receptor expression was probably respon- 
siifle for the observed ifferences in the magnitude of the effects 
ol atropine, NMS, AF-DX 116 and QNB on the accumulation 
oJ inositol phosphates in these two kinds of cells. 
Two main conclusions may be drawn from the present data. 
(a) Muscarinic receptors of the M1-M 4 subtypes expressed in 
genetically engineered CHO cells, and also native muscarinic 
receptors of the M2 subtype expressed in cardiomyocytes in
c~lture are constitutively active and their activity can be re- 
vcaled by the muscarinic antagonists atropine and NMS and, 
le~s systematically, QNB and AF-DX 116. Constitutive activity 
ol the receptors maintains light inhibition of the synthesis of 
c.~ clic AMP by the M 2 and M4 receptor subtypes and slight 
s imulat ion of phosphoinositide hydrolysis by the M~ and 
M3 receptor subtypes in the absence of a receptor agonist. (b) 
M uscarinic antagonists differ in their effect on the constitutive 
a, tivity of muscarinic receptors. While atropine and NMS be- 
h, ved as negative antagonists on all cell types and receptor 
sl~btypes applied in the present study, QNB and AF-DX 116 
b, haved as neutral antagonists in some and as negative antag- 
o fists in other models. 
The degree of the spontaneous activity of muscarinic recep- 
t(,rs is likely to depend on many factors and its extent and 
si!,)nificance in the various types of cells of multicellular organ- 
is~ns in vivo are difficult to predict and will have to be deter- 
n ined by direct measurements. Apparently, the constitutive 
a, tivity of muscarinic receptors has to be taken into account 
it: explanations of metabolic and functional events in cells and 
n uscarinic antagonists have to be evaluated not only with re- 
g, rd to their potency and subtype selectivity, but also with 
rt gard to their influence on the equilibrium between the recep- 
t(rs in the active and inactive conformations. 
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